CKPT Checkpoint Therapeutics Inc. Final Profit

Corporate emblem and logo of Checkpoint Therapeutics, Inc. (CKPT)

Is it worth investing in a business creating affordable cancer immunotherapy methods? The profit levels of Checkpoint Therapeutics (CKPT) on this chart provide the answer, while the value of -0.06 shows the current metric. The growth of Checkpoint Therapeutics (CKPT) is hindered by international component supply challenges and FDA delays, as well as pressure from pharmaceutical behemoths.

CKPT (Checkpoint Therapeutics) Net Profit history from 07/04/2022 to 06/07/2025

Analytical breakdowns and data insights for company Checkpoint Therapeutics, Inc. (CKPT)

- stock value and consensus price forecast:
Market Price Checkpoint Therapeutics Inc|CKPT - Price Target Chart
- market capitalization data:
Market Value Checkpoint Therapeutics Inc|CKPT - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Checkpoint Therapeutics|CKPT - Book Capitalization|Market Cap to Net Assets Ratio checkpointtx.com|CKPT - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Checkpoint Therapeutics|CKPT - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Checkpoint Therapeutics Inc.|CKPT - Company Aggregate Debts|Debts to Book Value Checkpoint Therapeutics Inc|CKPT - Company Long-Term Debts|Company Current Liabilities Checkpoint Therapeutics|Intermediate Coverage Ratio checkpointtx.com
- net income and valuation multiples indicators:
CKPT - Net Profit
Fundamental valuation:CKPT Checkpoint Therapeutics Inc
Manufactured product of Checkpoint Therapeutics Inc.

This metric aggregates the daily volume of the company's actual cash inflows, allowing investors to objectively assess trend sustainability or a financial crisis phase through net revenue dynamics. By analyzing the profits of Checkpoint Therapeutics (CKPT), you measure the actual efficiency of asset monetization, which is critical for Checkpoint Therapeutics (CKPT) given the inelastic demand for the unique drug cosibelimab for skin cancer therapy.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|Net Income sellaslifesciences.com SLS|Net Profit ACTU (Actuate Therapeutics)|Final Profit CTOR|TuHURA - Net Profit|Company Net Income Protara Tx|FATE: Net Profit|Net Income Aadi Bioscience|Company Net Income TScan Therapeutics Inc|Net Profit Champions Oncology Corp|Company Net Income XBiotech Inc. (XBIT)|CVM: Profit After Tax|Company Net Income OS Therapies Incorporated OSTX|Radiopharm Theranostics Ltd (RADX) - Company Net Income|Artiva - Net Profit|Net Financial Result Adlai Nortye Ltd. ANL|Veru Pharma (VERU) - Company Net Income|Company Profit TPST|Net Income XLO|RENB (Enochian BioSciences) - Profit After Payment of Taxes|Net Income MURA (Mural Oncology plc)|KAPA (kairospharma.com) - Final Profit|OnKure Therapeutics - Net Income|Profit After Payment of Taxes GDTC (CytoMed Therapeutics Ltd)|Curis Corp - Net Profit|Final Profit APLM (Apollomics, Inc.)|THAR: Net Profit|Company Net Income Advanced Biomed (ADVB)|Company Net Income Genprex, Inc|CLDI: Final Profit|Net Profit SBFM|Net Profit xeneticbio.com (XBIO)|Company Net Income Salarius Pharmaceuticals, Inc. SLRX|PPBT (Purple Biotech Ltd) - Profit After Tax|AON - Net Profit|Company Net Income BeiGene Ltd|ELEV (Elevation Oncology, Inc.) - Net Income|iCAD (ICAD) - Net Profit|Net Income IKNA|NTBL (Notable Labs Ltd) - Profit After Payment of Taxes|Net Profit VIRX|Net Financial Result MorphoSys Corporation|Net Profit NAYA (NAYA Biosciences)|AAPGV - Net Income